{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:05:04Z","timestamp":1786446304650,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T00:00:00Z","timestamp":1465257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12149-016-1093-8","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T09:43:17Z","timestamp":1465292597000},"page":"453-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases"],"prefix":"10.1007","volume":"30","author":[{"given":"Keisuke","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kaneta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shizukuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Zurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,7]]},"reference":[{"issue":"14","key":"1093_CR1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1517\/14656566.2014.955016","volume":"15","author":"PG Turner","year":"2014","unstructured":"Turner PG, O\u2019Sullivan J. Radium-223 dichloride for the treatment of metastatic prostate cancer. Expert Opin Pharmacother. 2014;15(14):2105\u201311.","journal-title":"Expert Opin Pharmacother"},{"key":"1093_CR2","doi-asserted-by":"crossref","unstructured":"1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9. Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):9\u201310.","DOI":"10.1200\/jco.2014.32.4_suppl.9"},{"key":"1093_CR3","doi-asserted-by":"crossref","unstructured":"Anido Herranz U, Fernandez Calvo O, Afonso Afonso FJ, Rodriguez Martinez de Llano S, Lazaro Quintela M, Leon Mateos L et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015; 1\u201310.","DOI":"10.1586\/14737140.2015.999045"},{"issue":"12","key":"1093_CR4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"P Hoskin","year":"2014","unstructured":"Hoskin P, Sartor O, O\u2019Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397\u2013406.","journal-title":"Lancet Oncol."},{"issue":"7","key":"1093_CR5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738\u201346.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1093_CR6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40265-014-0198-4","volume":"74","author":"M Shirley","year":"2014","unstructured":"Shirley M, McCormack PL. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs. 2014;74(5):579\u201386.","journal-title":"Drugs."},{"issue":"4","key":"1093_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00120-014-3436-1","volume":"53","author":"H Heinzer","year":"2014","unstructured":"Heinzer H, Konig F, Klutmann S. Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases. Urologe A. 2014;53(4):519\u201323.","journal-title":"Urologe A."},{"issue":"2","key":"1093_CR8","first-page":"252","volume":"44","author":"G Henriksen","year":"2003","unstructured":"Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252\u20139.","journal-title":"J Nucl Med"},{"issue":"2","key":"1093_CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-015-0495-4","volume":"18","author":"S Nilsson","year":"2016","unstructured":"Nilsson S. Radionuclide therapies in prostate cancer: integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2016;18(2):14.","journal-title":"Curr Oncol Rep."},{"issue":"1","key":"1093_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/PPO.0b013e318282479b","volume":"19","author":"D Brady","year":"2013","unstructured":"Brady D, Parker CC, O\u2019Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 2013;19(1):71\u20138.","journal-title":"Cancer J"},{"issue":"4","key":"1093_CR11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1060028014565444","volume":"49","author":"S McGann","year":"2015","unstructured":"McGann S, Horton ER. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. Ann Pharmacother. 2015;49(4):469\u201376.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1093_CR12","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1093_CR13","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00259-013-2427-6","volume":"40","author":"JA Carrasquillo","year":"2013","unstructured":"Carrasquillo JA, O\u2019Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1093_CR14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","volume":"56","author":"SJ Chittenden","year":"2015","unstructured":"Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl Med. 2015;56(9):1304\u20139.","journal-title":"J Nucl Med"},{"key":"1093_CR15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.6028\/jres.120.004","volume":"120","author":"BE Zimmerman","year":"2015","unstructured":"Zimmerman BE, Bergeron DE, Cessna JT, Fitzgerald R, Pibida L. Revision of the NIST standard for 223Ra: new measurements and review of 2008 data. J Res Natl Inst Stand Technol. 2015;120:1304\u20139.","journal-title":"J Res Natl Inst Stand Technol."},{"issue":"2","key":"1093_CR16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","volume":"40","author":"M Lassmann","year":"2013","unstructured":"Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging. 2013;40(2):207\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1093_CR17","unstructured":"Bayer Healthcare. Xofigo\u2014full prescribing information. 2013. http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Xofigo_PI.pdf ."}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-016-1093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-016-1093-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-016-1093-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T09:56:07Z","timestamp":1568022967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-016-1093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s12149-016-1093-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,7]]}}}